


bPRIDE

blood PProtein Identification to Discriminate dEmentias

Dementia is a group of disorders characterized by severe memory loss ultimately impairing daily life activities. Major forms are Alzheimer’s disease, Lewy body dementia, and frontotemporal dementia. Each dementia type is caused by different biological factors and therefore requires a specific treatment targeting these factors. To develop effective treatment, it is required to precisely diagnose each dementia type in the earliest possible stage.

bPRIDE will generate and validate blood tests for early and specific diagnosis of the major dementia types. Blood analysis is widely accepted for repetitive monitoring. To successfully achieve these aims, bPRIDE will analyze >1000 blood proteins in >1000 patients in different stages of these different dementias. This will be done using novel, extremely sensitive technologies. Specific and early diagnosis will empower patients by being timely informed. Moreover, it will allow to assign the most suitable novel treatments to the right patients, strongly improving the successful development of such potential therapies.




Total Funding : 1.8 M€

Duration : 3 years

Coordinator : Prof. Dr. Charlotte Teunissen

☎ : +31-20-4443680

✉ : c.teunissen@vumc.nl



Co- Coordinator : Dr. Marta del Campo

☎ : +34913724700 Ext: 14992

✉ : marta.campomilan@ceu.es

Consortium Members



Prof. Dr. Charlotte Teunissen

Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, the Netherlands



Dr. N. Mattsson, MD

Lund University, Sweden



Prof. Dr. C. Masters, MD

Florey Institute and University of Melbourne, Australia



Prof. Dr. M. Otto

Department of Neurology, University clinic of Ulm, Germany



Dr. A. Lleo

Institut Recerca del'Hospital de la Santa Creu i Sant Pau, Spain



Prof. L. Parnetti, MD

University of Perugia, Italy



Prof. Dr. Hort

Charles University, 2nd Medical Faculty, Czech Republic
